{"pmid":32343775,"title":"SARS-CoV-2 Serology: Much Hype, Little Data.","text":["SARS-CoV-2 Serology: Much Hype, Little Data.","Clin Chem","Farnsworth, Christopher W","Anderson, Neil W","32343775"],"journal":"Clin Chem","authors":["Farnsworth, Christopher W","Anderson, Neil W"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343775","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/clinchem/hvaa107","keywords":["covid-19","serology"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1665351883973197825,"score":8.574329,"similar":[{"pmid":32283141,"title":"Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","text":["Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.","J Infect","Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong","32283141"],"abstract":["An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application."],"journal":"J Infect","authors":["Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283141","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.051","keywords":["colloidal gold-based","covid-19","immunochromatographic strip","real-time rt-pcr","sars-cov-2","serology"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","China","ICG strip"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636703988514819,"score":65.71771},{"pmid":32196430,"title":"Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","text":["Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.","Emerg Microbes Infect","Loeffelholz, Michael J","Tang, Yi-Wei","32196430"],"abstract":["The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients."],"journal":"Emerg Microbes Infect","authors":["Loeffelholz, Michael J","Tang, Yi-Wei"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196430","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1745095","keywords":["covid-19","human coronavirus","poct","sars-cov-2","real-time pcr","serology"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640930736504833,"score":43.140434}]}